Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

VEGFR, MEK, Other Inhibitors Could Treat CML in Blast Crisis

  • Cancer Network Staff
May 13, 2015
  • Chronic Myeloid Leukemia, Hematologic Cancer Targets, Hematologic Malignancies, Leukemia & Lymphoma

A new study using chronic myeloid leukemia in blast crisis (CML BC) cells has identified existing anticancer agents that may provide benefit to patients with this difficult-to-treat disease. Tyrosine kinase inhibitors (TKIs) focused on BCR-ABL1 showed promise, as did vascular endothelial growth factor receptor (VEGFR) inhibitors and other agents.

TKI therapy has led to dramatic improvements in outcome for chronic phase CML patients. “Despite the treatment breakthroughs in chronic phase CML, advanced phase and blast crisis remain a therapeutic challenge,” wrote study authors led by Kimmo Porkka, MD, PhD, of the University of Helsinki in Finland. CML BC patients tend to respond less favorably to TKI therapy, and when those agents fail there are few other options. “None of the current treatment options are significantly effective in CML BC.”

In this study, researchers used high-throughput drug sensitivity and resistance testing of primary patient samples to identify agents that might help with CML BC patients. Results were published online ahead of print in Blood Cancer Journal.

The study included three distinct CML cell lines representing blast phase disease, as well as mononuclear cells from three CML BC patients and nine healthy donors. The analysis included 295 anticancer agents, with closer testing done on the 30 most promising candidate drugs.

The CML BC cell lines showed the most sensitivity to BCR-ABL1 inhibitors including nilotinib and ponatinib. The other major drug class showing responses was VEGFR inhibitors, such as tivozanib, axitinib, and nintedanib. One of the three cell lines was highly sensitive to BCL2 inhibitors including venetoclax and navitoclax. The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor also showed high activity across all cell lines.

In the patient samples, all showed some sensitivity to BCR-ABL1 inhibitors; only ponatinib was effective in all of the patient samples. A group of three MEK inhibitors—refametinib, trametinib, and TAK-733—were among the most selective drugs in all three of the primary CML BC cases, and VEGFR inhibitors also were effective at inhibiting cell growth.

“New promising candidate compound classes such as VEGFR, NAMPT, and MEK inhibitors were identified for CML BC,” the authors concluded. “These drugs were highly sensitive in most samples (including TKI resistant patient samples), warranting their further evaluation as combination regimens and paving the way for proof-of-concept clinical studies.”

Related Articles

  • FDA Grants Fast-Track Designation to CX-01 for Acute Myeloid Leukemia
  • MMG49 Identified as a New Target in Multiple Myeloma
  • Link Between Fanconi Anemia Genetic Mutations and Cancer Risk
  • FDA Approves New Acute Lymphoblastic Leukemia Treatment
  • FDA Approves New Targeted Agent for Acute Myeloid Leukemia

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".